Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials UsingHIVRecent Infection Assays: A Consensus Statement from the ForumHIVPrevention Trial Design Project

Autor: Neil, Parkin, Fei, Gao, Eduard, Grebe, Amy, Cutrell, Moupali, Das, Deborah, Donnell, Ann, Duerr, David V, Glidden, James P, Hughes, Jeffrey, Murray, Michael N, Robertson, Joerg, Zinserling, Joseph, Lau, Veronica, Miller, Sally, Hodder
Rok vydání: 2023
Předmět:
Zdroj: Clinical Pharmacology & Therapeutics.
ISSN: 1532-6535
0009-9236
Popis: Standard-of-care HIV pre-exposure prophylaxis (PrEP) is highly efficacious, but uptake of and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP products will require innovation to avoid the unpractically large sample sizes in noninferiority trials. We propose estimating HIV incidence in people not on PrEP as an external counterfactual to which on-PrEP incidence in trial subjects can be compared. HIV recent infection testing algorithms (RITAs), such as the limiting antigen avidity assay plus viral load used on specimens from untreated HIV positive people identified during screening, is one possible approach. Its feasibility is partly dependent on the sample size needed to ensure adequate power, which is impacted by RITA performance, the number of recent infections identified, the expected efficacy of the intervention, and other factors. Screening sample sizes to support detection of an 80% reduction in incidence for 3 key populations are more modest, and comparable to the number of participants in recent phase III PrEP trials. Sample sizes would be significantly larger in populations with lower incidence, where the false recency rate is higher or if PrEP efficacy is expected to be lower. Our proposed counterfactual approach appears to be feasible, offers high statistical power, and is nearly contemporaneous with the on-PrEP population. It will be important to monitor the performance of this approach during new product development for HIV prevention. If successful, it could be a model for preventive HIV vaccines and prevention of other infectious diseases.
Databáze: OpenAIRE
Externí odkaz: